Nabriva Therapeutics Ag Stock Shares Owned By Insiders
| NBRVDelisted Stock | USD 1.62 0.01 0.61% |
Nabriva Therapeutics AG fundamentals help investors to digest information that contributes to Nabriva Therapeutics' financial success or failures. It also enables traders to predict the movement of Nabriva Stock. The fundamental analysis module provides a way to measure Nabriva Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nabriva Therapeutics stock.
Nabriva |
Nabriva Therapeutics AG Company Shares Owned By Insiders Analysis
Nabriva Therapeutics' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Nabriva Therapeutics Shares Owned By Insiders | 0.96 % |
Most of Nabriva Therapeutics' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nabriva Therapeutics AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
CompetitionBased on the latest financial disclosure, 0.96% of Nabriva Therapeutics AG are shares owned by insiders. This is 93.68% lower than that of the Pharmaceuticals sector and 93.23% lower than that of the Health Care industry. The shares owned by insiders for all United States stocks is 90.49% higher than that of the company.
Nabriva Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nabriva Therapeutics' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nabriva Therapeutics could also be used in its relative valuation, which is a method of valuing Nabriva Therapeutics by comparing valuation metrics of similar companies.Nabriva Therapeutics is currently under evaluation in shares owned by insiders category among its peers.
Nabriva Fundamentals
| Return On Equity | -2.69 | |||
| Return On Asset | -0.65 | |||
| Profit Margin | (1.48) % | |||
| Operating Margin | (1.29) % | |||
| Current Valuation | 3.29 M | |||
| Shares Outstanding | 3.2 M | |||
| Shares Owned By Insiders | 0.96 % | |||
| Shares Owned By Institutions | 8.77 % | |||
| Number Of Shares Shorted | 44.59 K | |||
| Price To Earning | (0.48) X | |||
| Price To Book | 0.24 X | |||
| Price To Sales | 0.17 X | |||
| Revenue | 35.67 M | |||
| Gross Profit | (10.23 M) | |||
| EBITDA | (54.7 M) | |||
| Net Income | (57.19 M) | |||
| Cash And Equivalents | 20.04 M | |||
| Cash Per Share | 7.53 X | |||
| Total Debt | 5.22 M | |||
| Debt To Equity | 0.21 % | |||
| Current Ratio | 2.81 X | |||
| Book Value Per Share | (1.36) X | |||
| Cash Flow From Operations | (36.71 M) | |||
| Short Ratio | 8.58 X | |||
| Earnings Per Share | (19.67) X | |||
| Price To Earnings To Growth | (0.06) X | |||
| Target Price | 1.0 | |||
| Number Of Employees | 39 | |||
| Beta | 1.56 | |||
| Market Capitalization | 4.55 M | |||
| Total Asset | 31.77 M | |||
| Retained Earnings | (652.86 M) | |||
| Working Capital | 3.5 M | |||
| Current Asset | 83 M | |||
| Current Liabilities | 14 M | |||
| Z Score | -32.68 | |||
| Net Asset | 31.77 M |
About Nabriva Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nabriva Therapeutics AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nabriva Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nabriva Therapeutics AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Other Consideration for investing in Nabriva Stock
If you are still planning to invest in Nabriva Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Nabriva Therapeutics' history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Transaction History View history of all your transactions and understand their impact on performance |